| NCT03517449 |
Ⅲ |
KEYNOTE-775:帕博利珠单抗+仑伐替尼vs.脂质体多柔比星或紫杉醇 |
| NCT03884101 |
Ⅲ |
LEAP-001:帕博利珠单抗+仑伐替尼vs.卡铂+紫杉醇 |
| NCT02549209 |
Ⅲ |
NRG-GY018:卡铂+紫杉醇+帕博利珠单抗vs.卡铂+紫杉醇+安慰剂 |
| NCT03981796 |
Ⅲ |
RUBY:卡铂+紫杉醇+多塔利单抗vs.卡铂+紫杉醇+安慰剂 |
| NCT03603184 |
Ⅲ |
AtTEND:卡铂+紫杉醇+阿替利珠单抗vs.卡铂+紫杉醇+安慰剂 |
| NCT03526432 |
Ⅱ |
阿替利珠单抗+贝伐珠单抗治疗晚期EC和癌肉瘤 |
| NCT03951415 |
Ⅱ |
度伐利尤单抗+奥拉帕利治疗晚期EC和癌肉瘤 |
| NCT03694262 |
Ⅱ |
EndoBARR:阿替利珠单抗、贝伐珠单抗和卢卡帕尼治疗晚期EC和癌肉瘤 |
| NCT03572478 |
Ⅰ/Ⅱ |
卢卡帕尼和纳武利尤单抗疗晚期EC |
| NCT02912572 |
Ⅱ |
阿维鲁单抗治疗MSS型、MSI-H型和POLE突变晚期EC,阿维鲁单抗+他拉唑帕尼治疗MSS型晚期EC |
| NCT03835819 |
Ⅱ |
Mirvetuximab soravtansine+帕博利珠单抗治疗FRα阳性、晚期、MSS型EC |
